Researchers evaluated data from 25 different randomized clinical trials, sharing their findings virtually at EuroPCR 2021. 

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

Patients given the SGLT2 inhibitor did experience improved outcomes, the researchers noted, but none of the differences were statistically significant. 

Researchers tracked data from more than 1,500 patients who underwent a successful TAVR procedure from 2016 to 2019. 

This secondary analysis of data from the FIDELIO-DKD trial was presented May 17 at ACC.21 and published in the Journal of the American College of Cardiology. 

The solution has still only been approved in the United States for investigational use. 

The study's authors believe they are the first group to investigate the real-time relationship between alcohol consumption and AFib events.

Researchers explored data from the GALACTIC-HF trial to evaluate how the severity of a patient's reduced ejection fraction impacts the benefits of omecamtiv mecarbil.

“This is a procedure that’s done once, and it keeps giving a benefit over time,” one researcher said. “This is going to prevent thousands of strokes.”

The final rule would eliminate lag time between the FDA approving new technology and the Centers for Medicare & Medicaid Services paying for it.